Velagluceraza alfa
Prijeđi na navigaciju
Prijeđi na pretragu
| Klinički podaci | |
|---|---|
| Robne marke | Imiglucerase, VPRIV |
| AHFS/Drugs.com | alfa.html Monografija |
| Identifikatori | |
| CAS broj | 884604-91-5 |
| ATC kod | nije dodeljen |
| DrugBank | DB06720 |
| ChEMBL[1] | CHEMBL1201865 
|
| Hemijski podaci | |
| Formula | C2532H3850N672O711S16 |
| Mol. masa | 55,.5 Da (neglikozilisan) |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 11-12 minuta |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Intravenozno |
Velagluceraza alfa (VPRIV) jeste hidrolitički lizozomalni glukocerebrozidno specifični enzim, koji je rekombinantna forma glukocerebrozidaze. Ovaj lek se koristi kao terapija dugotrajne enzimske zamene za obolele od Gaučerove bolesti tipa 1. On ima identičnu aminokiselinsku sekvencu sa prirodnim enzimom.[2] Odobren je za upotrebu u SAD februara 2010.[3][4][5][6][7]
Reference[uredi | uredi kod]
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ University of Birmingham: Velaglucerase alfa for type 1 Gaucher’s disease Arhivirano 2011-05-05 na Wayback Machine-u
- ↑ Medical News Today: Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease Arhivirano 2020-09-16 na Wayback Machine-u, 27 February 2010
- ↑ Pastores GM: Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease. Curr Opin Investig Drugs. 2010 Apr;11(4):472-8. PMID 20336596
- ↑ Vairo F, Netto C, Dorneles A, Mittelstadt S, Wilke M, Doneda D, Michelin K, Ribeiro CB, Quevedo A, Vieira T, Nalin T, Lueska S, Schwartz IV: Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment. JIMD Rep. 2013 Feb 21. PMID 23430813
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
Literatura[uredi | uredi kod]
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
